David Hoang
Stock Analyst at Deutsche Bank
(1.96)
# 3,033
Out of 4,937 analysts
40
Total ratings
41.94%
Success rate
-7.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $55 | $34.21 | +60.77% | 3 | Jul 10, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Hold | $50 → $25 | $18.23 | +37.14% | 7 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $24.60 | +42.28% | 5 | May 21, 2025 | |
| ALKS Alkermes | Maintains: Buy | $40 → $52 | $26.71 | +94.68% | 2 | Mar 27, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $33.43 | +100.42% | 3 | Feb 11, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $111 | $45.95 | +141.57% | 1 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $13.96 | +122.06% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $14.74 | +340.98% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $104.80 | +67.94% | 4 | Feb 11, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Buy | $12 | $12.74 | -5.81% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $125.01 | +26.39% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.36 | +414.71% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.29 | +154.37% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.14 | +409.55% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $438.93 | -49.88% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $16.42 | +387.21% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $1.76 | +70.45% | 1 | Dec 7, 2022 |
Harmony Biosciences Holdings
Jul 10, 2025
Maintains: Buy
Price Target: $54 → $55
Current: $34.21
Upside: +60.77%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Hold
Price Target: $50 → $25
Current: $18.23
Upside: +37.14%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $24.60
Upside: +42.28%
Alkermes
Mar 27, 2025
Maintains: Buy
Price Target: $40 → $52
Current: $26.71
Upside: +94.68%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $33.43
Upside: +100.42%
Praxis Precision Medicines
Feb 11, 2025
Initiates: Buy
Price Target: $111
Current: $45.95
Upside: +141.57%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $13.96
Upside: +122.06%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $14.74
Upside: +340.98%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $104.80
Upside: +67.94%
Avadel Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $12.74
Upside: -5.81%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $125.01
Upside: +26.39%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.36
Upside: +414.71%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $6.29
Upside: +154.37%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $3.14
Upside: +409.55%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $438.93
Upside: -49.88%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $16.42
Upside: +387.21%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $1.76
Upside: +70.45%